BIAF 10-Q filed 2026-11-06 | Key takeaways
BIAF filed its 10-Q; the most relevant disclosure change is unchanged Going concern assessment: Management concludes substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance date given $2.6M cash on hand and expected operating expenditures.
Key takeaways
CyPath Lung test volume increased 37% year-over-year to 526 tests in Q3 2026, but revenue declined 8% to $273K due to lower average reimbursement per test
Going concern: Company had $2.6M cash at September 30, 2026 and projects sufficient cash only through March 2027 without additional financing
Warrant reclassification: $6.4M warrant liability was recorded and subsequently reclassified to equity following the August 2026 private placement; $1.2M loss on warrant liabilities recognized
Stock split: 1-for-15 reverse stock split completed August 21, 2026; shares outstanding reduced from 451,852 (June 30) to 1,166,625 (September 30) on post-split basis
Subsequent financing: October 2026 closed $4M registered direct offering with 116,545 shares and pre-funded warrants exercisable for 536,836 shares
Clinical trial: 11 clinical sites activated for CyPath Lung longitudinal trial including 9 VA/military medical centers
Operating expenses increased 23% to $4.6M in Q3 2026 driven by 75% increase in clinical development costs and 25% increase in SG&A
Key metrics
Disclosure changes
- Going concern assessment
Management concludes substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from issuance date given $2.6M cash on hand and expected operating expenditures.
The company projects sufficient cash only through March 2027 without additional financing, requiring continued capital raises. - Warrant liability reclassification
The company recorded a $6.4M warrant liability for liability-classified warrants issued in the August 2026 private placement, then reclassified to equity after certain terms resulted in conversion to equity classification; $1.2M loss on warrant liabilities recognized.
Warrant reclassification impacts equity and non-operating expense; $1.2M loss recognized in Q3 2026. - Reverse stock split
1-for-15 reverse stock split completed August 21, 2026; all share and per-share amounts retroactively adjusted.
Share count significantly reduced; affects per-share metrics and outstanding shares. - Operating lease right-of-use asset
Operating lease right-of-use asset increased to $730,572 at September 30, 2026 from $334,289 at December 31, 2025, due to new research laboratory lease entered in June 2026 and out-of-period adjustment for April 2024 lease amendment.
Operating lease liability increased proportionally; reflects expanded facility footprint. - Revenue concentration
Patient service fees (CyPath Lung and anatomical pathology) represent the majority of revenue; CyPath Lung direct billing was $273K in Q3 2026 (26% of revenue).
CyPath Lung revenue growing year-over-year but average reimbursement declining. - Subsequent events - October 2026 financing
In October 2026, company raised $4M through issuance of 116,545 common shares and 536,836 pre-funded warrants (all exercised at closing) plus unregistered warrants to purchase 980,072 shares at $6.122 exercise price.
Post-period financing extends cash runway; increases shares outstanding significantly.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BIAF in real time
Get material earnings, filing, IR, and earnings-call alerts by email.